http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 24 Sep 2024 08:02:16 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html <p>Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.</p><p> </p><p>“I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and http://www.streetinsider.com/Corporate+News/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html Tue, 24 Sep 2024 08:02:16 -0400 ALGS DRNA HAE PLRX http://www.streetinsider.com/Corporate+News/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html <p>Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.</p><p> </p><p>“I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and http://www.streetinsider.com/Corporate+News/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html Tue, 24 Sep 2024 08:02:16 -0400 ALGS DRNA HAE PLRX http://www.streetinsider.com/Corporate+News/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html <p>Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.</p><p> </p><p>“I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and http://www.streetinsider.com/Corporate+News/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html Tue, 24 Sep 2024 08:02:16 -0400 ALGS DRNA HAE PLRX http://www.streetinsider.com/Corporate+News/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html <p>Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.</p><p> </p><p>“I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and http://www.streetinsider.com/Corporate+News/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html Tue, 24 Sep 2024 08:02:16 -0400 ALGS DRNA HAE PLRX http://www.streetinsider.com/Management+Changes/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html <p>Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.</p><p> </p><p>“I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and http://www.streetinsider.com/Management+Changes/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html Tue, 24 Sep 2024 08:02:16 -0400 ALGS DRNA HAE PLRX http://www.streetinsider.com/Management+Changes/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html <p>Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.</p><p> </p><p>“I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and http://www.streetinsider.com/Management+Changes/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html Tue, 24 Sep 2024 08:02:16 -0400 ALGS DRNA HAE PLRX http://www.streetinsider.com/Management+Changes/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html <p>Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.</p><p> </p><p>“I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and http://www.streetinsider.com/Management+Changes/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html Tue, 24 Sep 2024 08:02:16 -0400 ALGS DRNA HAE PLRX http://www.streetinsider.com/Management+Changes/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html <p>Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.</p><p> </p><p>“I am excited to welcome Hardean to Aligos as our Chief Medical Officer, with expertise across liver indications, including both MASH and http://www.streetinsider.com/Management+Changes/Aligos+Therapeutics+%28ALGS%29+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23754026.html Tue, 24 Sep 2024 08:02:16 -0400 ALGS DRNA HAE PLRX http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Press+Releases/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html <p align="left">SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.<br /></p> <p>“I am excited to welcome Hardean to http://www.streetinsider.com/Globe+Newswire/Aligos+Therapeutics+Strengthens+Senior+Leadership+Team+with+the+Appointment+of+Hardean+Achneck%2C+MD+as+Chief+Medical+Officer/23753792.html Tue, 24 Sep 2024 08:00:00 -0400 ALGS ALGS DRNA HAE PLRX http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Dicerna+Pharmaceuticals++++++++++++++/19407710.html si-local-file:///var/storage/secattach/20220103/19407710.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Dicerna+Pharmaceuticals++++++++++++++/19407710.html Mon, 03 Jan 2022 06:09:00 -0400 DRNA http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Dicerna+Pharmaceuticals++++++++++++++/19407600.html si-local-file:///var/storage/secattach/20220103/19407600.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Dicerna+Pharmaceuticals++++++++++++++/19407600.html Mon, 03 Jan 2022 06:06:00 -0400 DRNA http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Dicerna+Pharmaceuticals++++++++++++++/19407601.html si-local-file:///var/storage/secattach/20220103/19407601.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Dicerna+Pharmaceuticals++++++++++++++/19407601.html Mon, 03 Jan 2022 06:06:00 -0400 DRNA http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Dicerna+Pharmaceuticals++++++++++++++/19407492.html si-local-file:///var/storage/secattach/20220103/19407492.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Dicerna+Pharmaceuticals++++++++++++++/19407492.html Mon, 03 Jan 2022 06:03:00 -0400 DRNA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dicerna+Pharmaceuticals+++For%3A+Dec+28++Filed+by%3A+Koppel+Adam/19401234.html si-local-file:///var/storage/secattach/20211229/19401234.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dicerna+Pharmaceuticals+++For%3A+Dec+28++Filed+by%3A+Koppel+Adam/19401234.html Wed, 29 Dec 2021 16:44:00 -0400 DRNA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dicerna+Pharmaceuticals+++For%3A+Dec+28++Filed+by%3A+Zeng+Ling/19400931.html si-local-file:///var/storage/secattach/20211229/19400931.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dicerna+Pharmaceuticals+++For%3A+Dec+28++Filed+by%3A+Zeng+Ling/19400931.html Wed, 29 Dec 2021 16:23:00 -0400 DRNA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dicerna+Pharmaceuticals+++For%3A+Dec+28++Filed+by%3A+Pagan+Douglas+W./19400918.html si-local-file:///var/storage/secattach/20211229/19400918.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dicerna+Pharmaceuticals+++For%3A+Dec+28++Filed+by%3A+Pagan+Douglas+W./19400918.html Wed, 29 Dec 2021 16:22:00 -0400 DRNA